Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States

Cancer

Volumn 117, Issue 11, 2011, Pages 2530-2540

  Shenoy, Pareen J ^a   Malik, Neha ^a   Nooka, Ajay ^a   Sinha, Rajni ^a   Ward, Kevin C ^b   Brawley, Otis W ^a,c   Lipscomb, Joseph ^b   Flowers, Christopher R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

Author keywords

Diffuse large B cell lymphoma; End Results program; Epidemiology; Incidence; Race; Surveillance; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEGRO; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREATMENT OUTCOME; UNITED STATES;

DIFFUSE LARGE B-CELL LYMPHOMA; END RESULTS PROGRAM; EPIDEMIOLOGY; INCIDENCE; RACE; SURVEILLANCE; SURVIVAL;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 79958757068     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25765     Document Type: Article

References (71)

1. American Cancer Society. Cancer Facts & Figures 2010. 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc- 024113.pdf Accessed June 19, 2010.
2. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2004:221-236.
3. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006. (Pubitemid 23095683)
4. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484-1493.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
6. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23:4117-4126. (Pubitemid 46211317)
7. Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis [abstract]. Proc Amer Soc Clin Oncol. 2004;22. Abstract 6500.
8. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127. (Pubitemid 46638950)
9. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw. 2010;8:288-334. Available at: http://www.jnccn.org/content/8/3/288.short. Accessed September 28, 2010.
10. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer Statistics for African Americans. CA Cancer J Clin. 2002;52:326-341. (Pubitemid 35446605)
11. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008;113:3231-3241.
12. *Stat Database: Incidence. SEER 9. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2010, based on the November 2009 submission. Available at: www.seer.cancer.gov/ publicdata. Accessed June 12, 2010.
13. *Stat Database: Incidence. SEER 13. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2010, based on the November 2009 submission. Available at: www.seer.cancer.gov/ publicdata. Accessed June 12, 2010.
14. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117-1121. (Pubitemid 30004912)
15. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251. (Pubitemid 30627732)
16. Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008;49: 2099-2107.
17. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
18. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708. (Pubitemid 47105409)
19. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001. 2004. Available at: http://seer.cancer.gov/csr/1975-2001/ Accessed November 13, 2009.
20. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602. (Pubitemid 15120476)
21. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986;104:757-765. (Pubitemid 16115037)
22. Browne MJ, Hubbard SM, Longo DL, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med. 1986;104:338-344. (Pubitemid 16163610)
23. Itoh K, Ohtsu T, Wakita H, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2000;11:1241-1247.
24. Linch DC, Smith P, Hancock BW, et al. A randomized British National Lymphoma Investigation trial of CHOP vs. A weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol. 2000;11(suppl 1):87-90.
25. Lorusso V, Palmieri G, Bianco AR, et al. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: a randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol. 2000;16:149-154.
26. Department of Health and Human Services. Rituximab. Product approval information. Licensing Action. 1997. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/appletter/1997/ritugen112697L.htm Accessed July 15, 2010.
27. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325-334. (Pubitemid 32783410)
28. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932. (Pubitemid 28446681)
29. Coiffier B, Lepage E, Herbrecht R, et al. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large-B-cell lymphoma (DLCL): interim results of a randomized GELA trial [abstract]. Blood. 2000;96:223A. Abstract 950.
30. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus 8 cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-116.
31. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
32. Brown CC. The statistical comparison of relative survival rates. Biometrics. 1983;39:941-948.
33. Flowers CR, Glover R, Lonial S, Brawley OW. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer. 2007;31: 182-201. (Pubitemid 46818422)
34. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
35. The A, Li Y, Reddy V, Davis R, Baird M, Foran J. A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB) [abstract]. Blood. 2007;110:4430.
36. Shenoy PJ, Bumpers K, King N, et al. Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: a matched cohort analysis [abstract]. Blood. 2009;114:1392.
37. Nabhan C, Morawa E, Bitran JD, et al. Patterns of care in follicular lymphoma (FL): are minorities being treated differently? Report from the National LymphoCare Study (NLCS) [abstract]. Blood. 2007;110:367.
38. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109: 1857-1861. (Pubitemid 46348180)
39. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
40. Percy C, Fritz A, Ries L. Conversion of neoplasms by topography and morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology, third edition. 2001. Available at: http://seer.cancer.gov/tools/conversion/ICDO2- 3manual.pdf Accessed March 19, 2009.
41. Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006;15:630-638.
42. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276. (Pubitemid 43053551)
43. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010 Oct 28. [Epub ahead of print].
44. Frankenfeld CL, Cerhan JR, Cozen W, et al. Dietary flavonoid intake and non-Hodgkin lymphoma risk. Am J Clin Nutr. 2008;87:1439-1445. (Pubitemid 351679788)
45. Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the Inter-Lymph Consortium. Int J Cancer. 2008;122:2062-2070. (Pubitemid 351441197)
46. De Roos AJ, Davis S, Colt JS, et al. Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma. Environ Res. 2010;110:70-78.
47. Kricker A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer. 2008;122:144-154. (Pubitemid 350209989)
48. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23:6524-6534. (Pubitemid 39265515)
49. Fisher SG, Fisher RI. The emerging concept of antigendriven lymphomas: epidemiology and treatment implications. Curr Opin Oncol. 2006;18:417-424. (Pubitemid 44199835)
50. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186-1191.
51. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88:645-656. (Pubitemid 26240396)
52. Vilchez RA, Madden CR, Kozinetz CA, et al. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet. 2002;359:817-823. (Pubitemid 34233750)
53. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6:451-458. (Pubitemid 351447318)
54. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398-405.
55. Ekstrom Smedby K, Vajdic CM, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008; 111:4029-4038.
56. Huang T, Shenoy PJ, Sinha R, Graiser M, Bumpers KW, Flowers CR. Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform. 2009;8:45-64.
57. Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev. 2009;18: 1259-1270.
58. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27-38. (Pubitemid 43025390)
59. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346: 1937-1947. (Pubitemid 34651353)
60. Chen Y, Han T, Iqbal J, et al. Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. Am J Clin Pathol. 2010;133:305-313.
61. Chan WJ. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol. 2010;92:219-230.
62. Powe NR, Cooper LA. Diversifying the racial and ethnic composition of the physician workforce. Ann Intern Med. 2004;141:223-224. (Pubitemid 39030873)
63. Lavizzo-Mourey R, Lumpkin JR. From unequal treatment to quality care. Ann Intern Med. 2004;141:221. (Pubitemid 39030871)
64. Groman R, Ginsburg J. Racial and ethnic disparities in health care: a position paper of the American College of Physicians. Ann Intern Med. 2004;141:226-232.
65. Kaplan SH, Greenfield S. The patient's role in reducing disparities. Ann Intern Med. 2004;141:222-223. (Pubitemid 39030872)
66. Hayes N, Rollins R, Weinberg A, et al. Cancer-related disparities: weathering the perfect storm through comprehensive cancer control approaches. Cancer Causes Control. 2005;16(suppl 1):41-50. (Pubitemid 41407873)
67. Reddy S, Shapiro M, Morton R Jr, Brawley OW. Prostate cancer in black and white Americans. Cancer Metastasis Rev. 2003;22:83-86. (Pubitemid 36363516)
68. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113. (Pubitemid 34437345)
69. Brawley OW. Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. J Clin Oncol. 2006;24:332-333. (Pubitemid 46630449)
70. Cooper LA, Hill MN, Powe NR. Designing and evaluating interventions to eliminate racial and ethnic disparities in health care. J Gen Intern Med. 2002;17:477-486. (Pubitemid 34989016)
71. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494-5502.